Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 72.2% in September

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 175,600 shares, a decline of 72.2% from the August 31st total of 632,400 shares. Based on an average daily volume of 4,500,000 shares, the short-interest ratio is currently 0.0 days. Approximately 4.3% of the company’s shares are sold short.

Hedge Funds Weigh In On Virax Biolabs Group

An institutional investor recently bought a new position in Virax Biolabs Group stock. Armistice Capital LLC acquired a new position in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 121,999 shares of the company’s stock, valued at approximately $178,000. Armistice Capital LLC owned about 7.87% of Virax Biolabs Group at the end of the most recent reporting period. Institutional investors own 8.61% of the company’s stock.

Virax Biolabs Group Stock Performance

Shares of VRAX stock remained flat at $1.93 during trading hours on Friday. The stock had a trading volume of 26,766 shares, compared to its average volume of 2,082,049. Virax Biolabs Group has a 12-month low of $0.60 and a 12-month high of $9.00. The business’s 50 day moving average is $2.66 and its two-hundred day moving average is $1.57.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.